LUXEMBOURG / Oct 29, 2025 / Business Wire / Auna S.A. (NYSE: AUNA) (“Auna” or “the Company”), a leading Latin American healthcare services and plan provider with operations in Mexico, Peru and Colombia, announced today the reporting dates for its Third Quarter 2025 financial results.
Earnings Release
Thursday, November 20, 2025
Time: After Market Close
Conference Call
Friday, November 21, 2025
Time: 8:00 a.m. ET
Quiet Period
Thursday, November 13 through Thursday, November 20, 2025
To participate, please dial
+1 888 596 4144 (Toll-Free)
+1 646 968 2525 (International)
Entry Passcode: 3884034
Webcast: click here
About Auna
Auna is a leading horizontally and vertically integrated healthcare platform in Latin America with operations in Mexico, Peru, and Colombia, focusing on high-complexity diseases. Our mission is to transform healthcare by providing access to a highly integrated healthcare offering in the underpenetrated markets of Spanish-speaking Americas. Founded in 1989, Auna has built one of Latin America′s largest modern healthcare platforms that consists of a horizontally integrated network of healthcare facilities and a vertically integrated portfolio of oncological plans and selected general healthcare plans. As of June 30th, 2025, Auna’s network included 31 healthcare network facilities, including hospitals, outpatient, prevention and wellness facilities with 2,333 beds, and 1.4 million healthcare plans. For more information visit www.aunainvestors.com
| Last Trade: | US$4.61 |
| Daily Change: | 0.01 0.22 |
| Daily Volume: | 78,038 |
| Market Cap: | US$138.300M |
November 20, 2025 November 20, 2025 September 24, 2025 August 19, 2025 May 20, 2025 | |

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load